Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer.

abstract CC BY

ObjectivesWe aimed to examine the association between homologous recombination repair (HRR)-related gene mutations and efficacy of oxaliplatin-based chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).ResultsNon-synonymous mutations in HRR-related genes were found in 13 patients and only one patient had a family history of pancreatic cancer. Eight patients with HRR-related gene mutations (group A) and nine without HRR-related gene mutations (group B) received oxaliplatin-based chemotherapy. Median progression-free survival after initiation of oxaliplatin-based chemotherapy was significantly longer in group A than in group B (20.8 months vs 1.7 months, p = 0.049). Interestingly, two patients with inactivating HRR-related gene mutations who received FOLFIRINOX as first-line treatment showed exceptional responses with respect to progression-free survival for > 24 months.Materials and MethodsComplete coding exons of 12 HRR-related genes (ATM, ATR, BAP1, BRCA1, BRCA2, BLM, CHEK1, CHEK2, FANCA, MRE11A, PALB2, and RAD51) were sequenced using a Clinical Laboratory Improvement Amendment-certified multiplex next-generation sequencing assay. Thirty consecutive PDAC patients who underwent this assay between April 2015 and July 2017 were included.ConclusionsOur results suggest that inactivating HRR-related gene mutations are predictive of response to oxaliplatin-based chemotherapy in patients with PDAC.

introduction CC BY

BRCA1 and BRCA2 play pivotal roles in DNA homologous recombination repair (HRR), and germline BRCA1/2 mutations reportedly increase risk of pancreatic ductal adenocarcinoma (PDAC). A large clinic-based cohort study enrolling 306 patients with PDAC reported the prevalence of pathogenic BRCA1/2 germline mutations to be 4.6% [1]. Moreover, several retrospective studies have indicated that patients with PDAC harboring germline BRCA1/2 mutations are more sensitive to platinum-based chemotherapy than those without the mutations [2–4]. In addition to BRCA1/2, other genes such as ATM, ATR, and PALB2 are involved in HRR [5]. In ovarian cancer, both germline and somatic mutations in HRR-related genes are predictive of response to platinum-based chemotherapy [6]. Therefore, it is reasonable to speculate that patients with PDAC harboring mutations in HRR-related genes in their tumor tissues are sensitive to platinum-based chemotherapy. Supporting this idea, Waddell et al. reported that four of five patients with PDAC who were deficient in BRCA1/2 or PALB2 responded to platinum-based chemotherapy [7]. Oxaliplatin, a third-generation diaminocyclohexane platinum compound, is now commonly used in patients with PDAC [8–12]. However, to date, studies in patients with PDAC investigating prevalence of HRR-related gene mutations in tumor tissues and their association with efficacy of oxaliplatin-based chemotherapy are sparse. Therefore, we aimed to evaluate the association between HRR-related gene mutations identified using a Clinical Laboratory Improvement Amendment (CLIA)-certified multiplex next-generation sequencing (NGS) assay (OncoPrimeTM) [13] and efficacy of oxaliplatin-based chemotherapy in patients with PDAC.

patient characteristics CC BY

Patient characteristics are summarized in Table 1, and characteristics of individual patients are shown in Table 2. The median age was 64 (range 39–81) years.

completion rate of the ngs-based multiplex gene assay CC BY

The NGS-based multiplex gene assay was performed using archival formalin-fixed paraffin-embedded (FFPE) tumor tissues (n = 21) or fresh frozen tumor tissues obtained from liver metastases (n = 5), primary sites (n = 3), and a lymph node metastasis (n = 1). The first NGS assay failed in four patients because of poor DNA quality, and a second assay was successfully completed in two patients using fresh frozen tissue obtained via fine-needle aspiration from a liver metastasis (n = 1) and a primary site (n = 1). The overall completion rate of the NGS assay was 93.3% (Figure 1).

identification of non-synonymous mutations in hrr-related genes CC BY

The identified HRR-related gene mutations and their corresponding ID, reported in the Catalogue of Somatic Mutations in Cancer (COSMIC) database and the reference single nucleotide polymorphism (rs) ID in dbSNP, are summarized in Table 3. BRCA2 was the most commonly mutated gene (n = 10), followed by ATM (n = 8), BRCA1 (n = 2), CHEK2 (n = 2), ATR (n = 1), and PALB2 (n = 1). In total, non-synonymous HRR-related gene mutations were identified in 13 patients (46.4%). Germline allele frequency of each variant in the normal population as reported in the Exome Aggregation Consortium (http://exac.broadinstitute.org/) and Human Genetic Variation Database (http://www.hgvd.genome.med.kyoto-u.ac.jp/) are also summarized in Table 3.

family history of cancer CC BY

Among the 28 patients evaluated, family history of any cancer and of pancreatic cancer within third-degree relatives was confirmed in 17 (60.7%) and four patients (14.3%), respectively. Of the 13 patients harboring HRR-related gene mutations, only one had a family history of pancreatic cancer (Table 1).

efficacy of oxaliplatin-based chemotherapy CC BY

Of the 28 patients evaluated, 17 received oxaliplatin-based chemotherapy. Treatment regimens are summarized in Table 2. Three radiologic responses and one tumor marker response (CA 19-9 and CEA decrease > 60%) were observed in patients harboring HRR-related gene mutations while only one radiologic response was observed in those without such mutations. Progression-free survival (PFS) and survival time after progression in individual patients are shown in Figure 2. Median PFS was significantly longer in patients with HRR-related gene mutations than those without mutations (20.8 months vs. 1.7 months, respectively; p = 0.049, Figure 3) and hazard ratio (HR) was 0.32 (95% confidence interval (CI), 0.10–1.06, p = 0.061).

discussion CC BY

In this study, non-synonymous HRR-related gene mutations were identified in 13 (46.4%) of 28 consecutive patients with PDAC who were evaluated using an NGS-based multiplex gene assay covering complete coding exons of 12 HRR-related genes. Among the 13 patients with HRR-related gene mutations, only one (7.6%) had a family history of pancreatic cancer (Table 2). In line with our current results, Shindo et al. recently reported that among 27 patients with pancreatic cancer harboring pathogenic germline mutations in BRCA1/BRCA2/ATM/PALB2, only three patients (11.1%) had a family history of pancreatic cancer [14]. These data suggest that prevalence of HRR-related gene mutations is not uncommon, even if a patient has no family history of pancreatic cancer. Efficacy of oxaliplatin-based chemotherapies such as FOLFIRINOX, FOLFOX, GEMOX, and SOX in pancreatic cancer has been tested in several clinical trials [8, 9, 11, 12]. Among these, only FOLFIRINOX exhibited clear significant benefit over gemcitabine monotherapy (control) in a large randomized clinical trial and has been recommended for a standard treatment regimen [8]. Conversely, SOX failed to exhibit benefit over S-1 monotherapy in a second-line setting in a randomized clinical trial and is not recommended as standard treatment in routine clinical practice [11]. However, in this study, we observed one patient with an inactivating HRR-related gene mutation (BRCA2 Q3026X) who did not respond to the standard chemotherapy of gemcitabine/nab-paclitaxel but exhibited a partial response to SOX (Figure 2, Case 14). These results suggested that an oxaliplatin-based regimen, which failed to demonstrate a positive result in a clinical trial involving random patients with PDAC, is still beneficial in patients harboring HRR-related gene mutations. Among 28 patients, 17 received oxaliplatin-based chemotherapy. In total, three of eight patients who harbored HRR-related gene mutations showed a radiologic response to oxaliplatin-based chemotherapy and one showed a CA19-9 and CEA decrease of > 60% at 8 weeks, which has been shown to be a predictor of better overall survival [15], whereas the response rate was 11.1% (1/9) among patients without such mutations. Interestingly, two patients with HRR-related gene mutations who received FOLFIRINOX as first-line treatment showed exceptional PFS responses for > 24 months (Figure 2, Cases 10 and 11). Because impaired HRR may confer sensitivity to platinum agents and topoisomerase inhibitors [5, 16, 17], patients with HRR-related gene mutations may experience greater benefit from FOLFIRINOX treatment. On the other hand, four patients with HRR-related gene mutations showed neither radiologic nor tumor marker response to oxaliplatin-based chemotherapy. One patient (Case 13) refused to continue chemotherapy after the first cycle of GEMOX due to its toxicity. The other three patients (Case 15, 16, 17), received oxaliplatin-based chemotherapy as third or later line treatment and this might have influenced the poor response. For example, Case 15 was obliged to discontinue chemotherapy after the first cycle of FOLFOX due to rapid deterioration of uncontrollable ascites. Therefore, to derive maximum benefit from oxaliplatin-based chemotherapy in patients with HRR-related gene mutations, it appears to be relevant to attempt this regimen at an earlier treatment time-point under better patient general status. Pathogenic germline BRCA1/2 mutations are listed among the genes recommended for reporting of secondary findings by the American College of Medical Genetics and Genomics (ACMG) [18], and we follow this recommendation in daily clinical practice. In this study, suspected pathogenic germline BRCA1/2 mutations that met the ACMG recommendations were found in five patients (Table 3, Cases 12, 14, 17, 24, and 26). However, except for case 24, four patients did not undergo the germline test primarily because the test results would not affect their own cancer treatment. We were able to conduct the additional germline DNA test in four patients who provided informed consent, and five of 10 HRR-related mutations were confirmed to be germline mutations (Table 3). Limitations of this study included a limited sample size, and differences in lines of treatment and oxaliplatin-based chemotherapy regimens among the patients. In addition, we could not eliminate the possibility that mutations identified in nine patients who did not undergo the germline test may have been derived from germline DNA. In summary, the status of HRR-related gene mutations was positively associated with oxaliplatin-based chemotherapy in patients with PDAC. Monitoring HRR-related genes using an NGS assay might be useful in selecting PDAC patients potentially sensitive to oxaliplatin-based chemotherapy. We are currently planning a prospective trial to verify the results reported here and further explore precision medicine in the field of pancreatic cancer.

patients CC BY

A total of 30 consecutive patients with histologically confirmed PDAC who underwent an NGS-based multiplex assay (OncoPrimeTM) at Kyoto University Hospital between April 2015 and July 2017 were eligible for this study.

ngs-based multiplex assay (oncoprime CC BY

An NGS-based multiplex assay (OncoPrimeTM) covers complete coding exons of 215 cancer-related genes and rearrangements in 17 frequently rearranged genes (Supplementary Table 1) [13, 19]. DNA extracted from archived FFPE tissue samples or fresh frozen tissue samples was used for this assay. NGS was performed in a CLIA-certified laboratory using Illumina HiSeq 2500 by EA Genomics (Morrisville, North Carolina, United States).

identification of hrr-related gene mutations CC BY

Twelve HRR-related genes included in OncoPrimeTM (ATM, ATR, BAP1, BRCA1, BRCA2, BLM, CHEK1, CHEK2, FANCA, MRE11A, PALB2, and RAD51) were evaluated in this study. Variant calling was performed using variant calling software (VarPROWL) in a CLIA-certified laboratory by EA Genomics as previously reported [13] based on the following workflow: Step 1: Remove all silent mutations in non-reference alleles, retaining mutations that are missense, are nonsense, or involve splicing junctions. Step 2: Remove all non-reference alleles that appear in > 1% of the population (high minor allele frequency) because they are likely germline events. Step 3: Remove all non-reference alleles with allele frequencies of < 4% and > 95%. This was performed because the limit of detection was 4% and alleles with > 95% frequency were most likely germline DNA because the sample material had at least 20% tumor content. Step 4: The identified mutations were prioritized based on their presence in the following databases: Online Mendelian Inheritance in Man (https://www.omim.org/), ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/), Clinical Trials.gov (https://clinicaltrials.gov/), Drug Bank (https://www.drugbank.ca/), COSMIC (http://cancer.sanger.ac.uk/cosmic), and the Cancer Genome Atlas (https://cancergenome.nih.gov/). After the filtering process mentioned above, non-synonymous mutations including variants of unknown significance were considered HRR-related gene mutations.

efficacy of oxaliplatin-based chemotherapy CC BY

Oxaliplatin-based chemotherapy includes oxaliplatin, irinotecan, fluorouracil, and l-leucovorin (FOLFIRINOX); gemcitabine and oxaliplatin (GEMOX); and S-1 and oxaliplatin (SOX) [8, 11, 12]. Standard doses and schedules of the regimens were adjusted at the discretion of the treating physicians based on incidence of adverse events and individual patient general status. Clinical data were retrieved using a prospective cohort database system (CyberOncology®; Cyber Laboratory Inc., Tokyo, Japan) and electronic medical records.

statistical analysis CC BY

Objective response was assessed based on the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 [20]. PFS was defined as the interval between date of initiation of oxaliplatin-based chemotherapy and date of disease progression or death due to any cause. Survival time after disease progression was defined as the interval between date of disease progression and death. Patients not experiencing disease progression or death were censored at the last follow-up visit. Median PFS was estimated using the Kaplan-Meier method, and differences were compared using the log-rank test. The hazard ratio and 95% confidence interval were calculated using Cox regression models. The data cutoff date was November 30, 2017. Statistical analyses were performed using R version 3.4.1.

ethics CC BY

This study was approved by the Ethics Committee of Kyoto University Graduate School of Medicine (G692) and conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent for the use of genomic and clinical data for research purposes.